| Literature DB >> 21463516 |
Katherine Kahn1, Gery Ryan, Megan Beckett, Stephanie Taylor, Claude Berrebi, Michelle Cho, Elaine Quiter, Allen Fremont, Harold Pincus.
Abstract
BACKGROUND: Translating the extraordinary scientific and technological advances occurring in medical research laboratories into care for patients in communities throughout the country has been a major challenge. One contributing factor has been the relative absence of community practitioners from the US biomedical research enterprise. Identifying and addressing the barriers that prevent their participation in research should help bridge the gap between basic research and practice to improve quality of care for all Americans.Entities:
Mesh:
Year: 2011 PMID: 21463516 PMCID: PMC3087703 DOI: 10.1186/1748-5908-6-34
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Benefits to community clinicians associated with their participation in clinical research
| Type of Benefit | How Clinicians Benefit |
|---|---|
| Benefits to the profession of clinical medicine and associated specialty organizations | • Contributes to the mission of medicine and improves the scientific basis for the practice of medicine. |
| • Facilitates clinicians' gaining support from professional organizations and NIH. | |
| • Allows clinicians to contribute to the development of new knowledge; research participation provides a mechanism for this to take place. | |
| • Support clinicians to learn and implement what's best for their patients. | |
| Benefits to clinicians in their role as clinicians | • Allows clinicians to remain current with new innovations. |
| • Affords intellectual stimulation, an often-welcomed change from demands of clinical practice. | |
| • Promotes affiliation with desirable colleagues and belonging to a community with other professionals. | |
| • Provides a second income stream, which diversifies financial risk. | |
| • Generates prestige of being engaged in research and professional recognition ( | |
| • Offers free medications and/or diagnostic and therapeutic interventions to participants of some studies. | |
| Benefits to clinicians in their role as managers of their practice settings | • With patients wanting more and payors giving less, clinicians have much to gain from evidence-based studies that delineate care known to improve outcomes. |
| • Many patients seek out clinicians who are at the cutting edge of research and thus provide access to the best diagnostic and treatment options, some of which may otherwise be unavailable. | |
| • Participation in clinical research serves as a marketing tool for clinicians to signal their clinics as outstanding. | |
| Benefits to clinicians in their interactions with managed care | • Clinician participation in research builds infrastructure that can facilitate engagement with managed care. |
| • Information systems improve with the data gathering and transfer associated with research. | |
| Benefits to clinicians in their efforts to improve the health of community populations | • Participation by a diverse set of clinicians and their patients is most likely to illuminate relationships between care and outcomes that apply to most patients seen in community practice. |
Content of interviews and types, and numbers of interviewees
| Number of interviews | |||
|---|---|---|---|
| Incentives and disincentives for provider participation, including organizational barriers and motivators | Best practices in community research networks, and how new provider networks might partner with these | Community clinicians (Individual primary care clinicians, dentists, nurse practitioners) and clinician organizations (health plans, large community practices) not currently participating in research | 37 |
| Strategies for provider participation and retention | Proposed provider effort as complementary to or in competition with existing clinician organizations; Liability and marketing concerns | Individual clinicians and health provider organizations already participating in clinical research | 30 |
| Ethical and professional issues | Optimal design for studies in community practices; Costs associated with conducting various types of clinical research studies in community settings | Leaders and coordinators of clinical research networks ( | 80 |
| Advantages and limitations of different types of research networks/organizations by study and provider type and the potential role of emerging information systems | Governance, oversight, and quality control for NCRA | Representatives of private-sector organizations ( | 77 |
| Specific recommendations to NIH on design of physician recruitment and incentives | Addressing privacy, HIPAA and institutional review boards issues | Representatives of public and government entities ( | 19 |
a A list of key issues discussed during early phases of interviews. See Appendix 1 for list of early phase interview informants.
b A list of key issues discussed during later interviews, after review of transcripts of early interviews. See Appendix 2 for list of later phase interview informants.
c Interviewees were selected from a listing developed by key stakeholders, authors of pertinent publications, recommendations by national organizations, and by recommendations by NIH Institute Leaders. Contact with members of this list, supplemented by snowball sampling, was used to generate the list of interviewees table.
Barriers clinicians have identified regarding participation in clinical research
| Study questions | |
| Study design feasibility | Study inclusion and exclusion criteria make most community practice patients ineligible. |
| Clinician's relationships with clinical/scientific communities | Clinicians need reassurance that research engagement does not threaten the doctor-patient relationship. |
| Clinician and patient distrust of research | Equitable access to research opportunities & to care reflecting research findings will help address longstanding mistrust by clinicians and patients for research endeavors. |
| Data quality | Assuring data quality in office settings is challenging, particularly given the lack of uniformity of study design across studies. |
| Design efficiency | Adequate and efficient training for successful research participation is not readily available or pertinent to clinician practice settings. |
| Study costs | Costs and effort associated with transient research engagement are excessive. |
| Research training | Local research training efforts are not rigorous enough. |
| Assuring privacy | Accessing IRB and HIPAA certification is burdensome and time-consuming. |
| Research engagement | Research participation is isolating without systematic feedback about performance, data quality, and research findings. |
| Scheduling | There is no time to do research in a busy practice. |
| Reimbursement | Clinical research participation will not be reimbursed adequately. |
| Liability | The adequacy of legal liability (insurance?) for research participation for practicing clinicians is murky. |
| Predictability | Unpredictable nature of research (sporadic study availability, changes in costs and reimbursement rates). |
| Information availability | Information is not readily available (study questions, protocols, reimbursement schedules, study-specific enrollment, data quality). |
Explanatory and practical clinical trials: Two options for clinical trials in community settings [7,42]
| Hypothesis and study questions are designed to improve the understanding of the mechanism by which an intervention works | Hypothesis and study questions are designed to facilitate decision making | |
| How effective is a treatment under ideal, experimental conditions? | How effective is a treatment in every-day practice? What are the risks, benefits, and costs in every-day practice? | |
| Rigorous inclusion/exclusion criteria to create a well-defined, homogenous sample of patients | Wide inclusion/exclusion criteria to reflect actual, often diverse, patient populations in clinical practices | |
| Homogeneous | Many and diverse | |
| Well-specified, precise protocol with limited variation allowed; often involves treatment vs. placebo | Well-specified, precise protocol allowing variation in implementation from site to site to capture actual patient and care characteristics; often compares existing, clinically-relevant, feasible treatment alternatives (often head-to-head) | |
| Enough to assemble a homogenous group that will enable a study of a relationship between a single intervention and a dominant outcome measure | Often requires large sample size to account for heterogeneity in sample and long-term nature of studies | |
| Well-defined; often a specific biological effect of an intervention | Often defined broadly in relation to patient's function or quality of life so effect sizes on personal and population health can be calculated |
Strategies to improve the predictability of research
| Strategies | Requirements |
|---|---|
| Make research-associated tasks explicit to clinicians prior to their agreeing to participate in a study | • Training requirements |
| • Mechanism for patient screening to determine study eligibility | |
| • Inclusion and exclusion criteria | |
| • Number of subjects stratified by clinical, demographic, & geographic categories | |
| • Expected patient visits and follow-up requirements | |
| • Data collection and transfer strategies | |
| • Adverse outcome protocols | |
| • Quality assurance requirements | |
| • Dissemination | |
| Establish | • Work with researchers & clinicians to establish a list of key research tasks |
| • Develop a taxonomy for assigning payment to these tasks | |
| • Develop payment rates based upon specialty, experience, & region | |
| • Assure clinicians are clear about study-specific-protocol services | |
| • Implement serial evaluations to test the payment rates |